Publications by authors named "Laura L Want"

Claim this Profile
S
Safety and Tolerability of Glucagon-Like Peptide-1 Receptor Agonists Utilizing Data from the Exenatide Clinical Trial Development Program.
Hui Peng, Laura L Want, Vanita R Aroda

Curr Diab Rep· May 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
O
Optimizing treatment success with an amylin analogue.
Laura L Want

Diabetes Educ· April 2008

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Case study 3: balancing act: using a team approach to achieve better glycemic control for the patient with type 2 diabetes.
Laura L Want

Diabetes Educ· May 2007

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Pramlintide: A new tool in diabetes management.
Laura L Want, Robert E Ratner

Curr Diab Rep· November 2006

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
O
Overview of diabetes.
Joan K Bardsley, Laura L Want

Crit Care Nurs Q· June 2004

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Impact of pramlintide on glucose fluctuations and postprandial glucose, glucagon, and triglyceride excursions among patients with type 1 diabetes intensively treated with insulin pumps.
Claresa Levetan, Laura L Want, Christian Weyer, Susan A Strobel, John Crean

Diabetes Care· January 2003

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Adjunctive therapy with the amylin analogue pramlintide leads to a combined improvement in glycemic and weight control in insulin-treated subjects with type 2 diabetes.
Robert E Ratner, Laura L Want, Mark S Fineman, Maggie J Velte, James A Ruggles

Diabetes Technol Ther· November 2002

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis